MeasurableQuantitativeAnnotation  

PubMed:32243238 JSONTXT 12 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
E1 1168-1173 entity denotes Fever
N1 1190-1192 num denotes 97
N2 1198-1200 num denotes 61
U1 1200-1201 unit denotes %
E2 1204-1209 entity denotes cough
N3 1213-1215 num denotes 88
N4 1221-1223 num denotes 56
U2 1223-1224 unit denotes %
E3 1227-1234 entity denotes dyspnea
N5 1238-1240 num denotes 52
N6 1246-1248 num denotes 33
U3 1248-1249 unit denotes %
E4 1252-1267 entity denotes lymphocytopenia
N7 1271-1273 num denotes 95
N8 1279-1281 num denotes 60
U4 1281-1282 unit denotes %
E5 1285-1319 entity denotes increased C-reactive protein level
N9 1323-1326 num denotes 139
N10 1332-1334 num denotes 88
U5 1334-1335 unit denotes %
E6 1342-1372 entity denotes elevated lactate dehydrogenase
N11 1376-1379 num denotes 128
N12 1385-1387 num denotes 81
U6 1387-1388 unit denotes %
U4 1586-1787 unit denotes PCR-positive and CT-positive patients, ground-glass opacities (GGO) were present in 58/58 (100%), multilobe and posterior involvement were both present in 54/58 (93%), bilateral pneumonia in 53/58 (91%
E1 1625-1653 entity denotes ground-glass opacities (GGO)
N1 1670-1672 num denotes 58
N2 1677-1680 num denotes 100
U1 1680-1681 unit denotes %
E2 1684-1719 entity denotes multilobe and posterior involvement
N3 1741-1743 num denotes 54
N4 1748-1750 num denotes 93
U2 1750-1751 unit denotes %
E4 1754-1773 entity denotes bilateral pneumonia
N7 1777-1779 num denotes 53
N8 1784-1786 num denotes 91
E3 1794-1825 entity denotes subsegmental vessel enlargement
N5 1838-1840 num denotes 52
N6 1845-1847 num denotes 89
U3 1847-1848 unit denotes %
R1 E1 N1 associateWith ground-glass opacities (GGO),58
R1 E1 N1 associateWith ground-glass opacities (GGO),58
R10 E4 N7 associateWith bilateral pneumonia,53
R10 E4 N7 associateWith bilateral pneumonia,53
R11 E4 N8 associateWith bilateral pneumonia,91
R11 E4 N8 associateWith bilateral pneumonia,91
R12 N8 U4 associateOf 91,"PCR-positive and CT-positive patients, ground-glass opacities (GGO) were present in 58/58 (100%), multilobe and posterior involvement were both present in 54/58 (93%), bilateral pneumonia in 53/58 (91%"
R12 N8 U4 associateOf 91,"PCR-positive and CT-positive patients, ground-glass opacities (GGO) were present in 58/58 (100%), multilobe and posterior involvement were both present in 54/58 (93%), bilateral pneumonia in 53/58 (91%"
R13 E5 N9 associateWith increased C-reactive protein level,139
R14 E5 N10 associateWith increased C-reactive protein level,88
R15 N10 U5 associateOf 88,%
R16 E6 N11 associateWith elevated lactate dehydrogenase,128
R17 E6 N12 associateWith elevated lactate dehydrogenase,81
R18 N12 U6 associateOf 81,%
R2 E1 N2 associateWith ground-glass opacities (GGO),100
R2 E1 N2 associateWith ground-glass opacities (GGO),100
R3 N2 U1 associateOf 100,%
R3 N2 U1 associateOf 100,%
R4 E2 N3 associateWith multilobe and posterior involvement,54
R4 E2 N3 associateWith multilobe and posterior involvement,54
R5 E2 N4 associateWith multilobe and posterior involvement,93
R5 E2 N4 associateWith multilobe and posterior involvement,93
R6 N4 U2 associateOf 93,%
R6 N4 U2 associateOf 93,%
R7 E3 N5 associateWith subsegmental vessel enlargement,52
R7 E3 N5 associateWith subsegmental vessel enlargement,52
R8 E3 N6 associateWith subsegmental vessel enlargement,89
R8 E3 N6 associateWith subsegmental vessel enlargement,89
R9 N6 U3 associateOf 89,%
R9 N6 U3 associateOf 89,%